US officials launch probe into falling German drug prices amid EU pharma push for competitiveness

US trade officials held a hearing on Tuesday about a possible investigation into the decline in Germany's payments for pharmaceuticals.

Testimony presented arguments both supporting and opposing the probe, reflecting concerns about pricing practices and market dynamics.

EU-based pharmaceutical executives are using the issue to call for greater competitiveness of European companies against the United States and China.

The outcome could influence cross-border drug pricing and regulatory approaches, though details remain under review.